Jylamvo

Dosage for Methotrexate is highly individualized and depends strictly on the condition being treated. A critical safety point is that for most non-oncological conditions, Methotrexate is taken ONCE WEEKLY, not daily. Taking Methotrexate daily for RA or psoriasis can lead to fatal toxicity.

• Rheumatoid Arthritis: The typical starting dose is 7.5 mg once weekly, administered either as a single oral dose or divided into three doses of 2.5 mg taken 12 hours apart. Your doctor may gradually increase the dose to a maximum of 20-25 mg per week based on clinical response and tolerance.
• Psoriasis: The starting dose is usually 10 mg to 25 mg once weekly. Healthcare providers often start with a small 'test dose' (e.g., 2.5 mg to 5 mg) to check for idiosyncratic reactions before proceeding to the full weekly dose.
• Oncology: Dosing varies widely. For choriocarcinoma, 15-30 mg daily for five days, repeated in cycles, is common. For leukemia maintenance, doses may be calculated based on body surface area (e.g., 20 mg/m² weekly).

Methotrexate is approved for use in children with polyarticular juvenile idiopathic arthritis (pJIA).

• Standard pJIA Dose: The recommended starting dose is 10 mg/m² once weekly. Dosage is adjusted based on the child's weight, body surface area, and response to the medication. Monitoring in children is particularly rigorous to ensure growth and development are not adversely affected.

Renal Impairment

Since Methotrexate is primarily cleared by the kidneys, dosage adjustments are mandatory for patients with decreased renal function.

• CrCl 60-80 mL/min: Reduce dose by 25%.
• CrCl 45-60 mL/min: Reduce dose by 50%.
• CrCl <45 mL/min: Use is generally avoided or requires extreme caution and significant dose reduction.

Hepatic Impairment

Methotrexate is potentially hepatotoxic. In patients with pre-existing liver disease (cirrhosis, hepatitis) or significant alcohol consumption, Methotrexate is generally contraindicated. If bilirubin is >5 mg/dL, the drug should not be administered.

Elderly Patients

Older adults often have reduced renal and hepatic reserves. Healthcare providers typically start elderly patients on the lowest possible dose and monitor more frequently for signs of early toxicity, such as mouth sores or low white blood cell counts.

• Timing: Choose a specific day of the week (e.g., 'Methotrexate Monday') to ensure you do not miss a dose or take it too frequently.
• Food: Methotrexate can be taken with or without food. However, taking it with a light meal may help reduce the nausea often associated with the drug.
• Hydration: It is vital to stay well-hydrated, especially on the day of your dose, to help the kidneys flush the medication out of your system.
• Folic Acid: Most doctors prescribe a daily folic acid supplement (usually 1 mg daily) to reduce the risk of side effects like mouth sores and GI upset. Note: Do not take folic acid on the same day as your Methotrexate dose if instructed by your doctor, though many modern protocols allow for daily use.
• Storage: Store tablets at room temperature, away from light and moisture. Keep out of reach of children, as even a small amount can be toxic to a child.

If you miss your weekly dose, take it as soon as you remember if it is within 24-48 hours. If more than two days have passed, contact your healthcare provider for instructions. NEVER double your dose to make up for a missed one, as this significantly increases the risk of bone marrow suppression.

Signs of Methotrexate overdose include severe nausea, vomiting, mouth ulcers, black or bloody stools, coughing up blood, and signs of infection (fever, chills). In the event of an overdose, emergency medical treatment is required. The 'antidote' used in clinical settings is Leucovorin (folinic acid), which provides a source of active folate that bypasses the block created by Methotrexate. Glucarpidase may also be used in cases of renal failure to rapidly lower plasma levels.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or frequency without medical guidance.

Many patients taking Methotrexate for autoimmune conditions will experience some level of side effects, particularly during the first few months of therapy. These are often manageable with the addition of folic acid.

• Gastrointestinal Upset: Nausea and vomiting are the most frequent complaints. This usually occurs within 24-48 hours after the weekly dose.
• Stomatitis (Mouth Sores): Small, painful ulcers may develop on the tongue or inside the cheeks. This is often a sign that folate levels are too low.
• Fatigue and 'Brain Fog': Many patients report feeling extremely tired or having difficulty concentrating the day after taking their dose, sometimes referred to as the 'Methotrexate hangover.'
• Elevated Liver Enzymes: Asymptomatic increases in ALT or AST levels are common and usually resolve with dose adjustment.

• Alopecia (Hair Thinning): While not as severe as with high-dose chemotherapy, some patients notice thinning of the hair.
• Photosensitivity: Increased sensitivity to sunlight, leading to easier sunburns or skin rashes.
• Dizziness and Headaches: These may occur shortly after administration.
• Leukopenia: A mild drop in white blood cell counts, which may slightly increase the risk of minor infections.

• Pneumonitis: An inflammation of the lungs that can cause a dry cough and shortness of breath. This is a medical emergency.
• Stevens-Johnson Syndrome (SJS): A severe, life-threatening skin reaction characterized by peeling skin and blisters.
• Encephalopathy: Primarily seen with high-dose intravenous or intrathecal use, leading to confusion or seizures.

> Warning: Stop taking Methotrexate and call your doctor immediately if you experience any of these symptoms.

• Signs of Infection: Fever, persistent sore throat, or chills. Methotrexate suppresses the immune system, making it harder to fight off even minor illnesses.
• Unusual Bleeding or Bruising: This may indicate thrombocytopenia (low platelet count), which increases the risk of internal bleeding.
• Severe Abdominal Pain: Could indicate GI perforation or severe hepatotoxicity.
• Yellowing of the Eyes/Skin (Jaundice): A primary sign of liver damage or failure.
• Shortness of Breath or Dry Cough: These can be early warning signs of Methotrexate-induced lung disease, which can be fatal if not treated.
• Dark Urine or Decreased Urination: Signs of potential kidney damage.

With prolonged use (years), Methotrexate carries specific risks that require ongoing monitoring:

• Liver Fibrosis and Cirrhosis: Chronic low-dose therapy can lead to scarring of the liver. This risk is higher in patients with obesity, diabetes, or a history of alcohol use.
• Secondary Malignancies: There is a slightly increased risk of developing certain lymphomas, although this is sometimes reversible upon stopping the drug.
• Bone Marrow Suppression: Chronic suppression of red cells, white cells, and platelets can occur, requiring periodic 'drug holidays.'

The FDA has issued several Black Box Warnings for Methotrexate due to its potential for severe toxicity:

1. 1Fetal Death and Teratogenicity: Methotrexate can cause severe birth defects or fetal death. It is strictly contraindicated in pregnancy.
2. 2Impaired Drug Elimination: Patients with renal impairment are at high risk for toxicity.

• Hepatotoxicity: Chronic use can lead to liver failure.
• Pulmonary Toxicity: Methotrexate-induced lung disease can occur at any time during therapy.
• GI Toxicity: Can lead to hemorrhagic enteritis and intestinal perforation.
• Bone Marrow Suppression: Can cause sudden, severe drops in blood cell counts.
• Secondary Infections: Increased susceptibility to opportunistic infections like Pneumocystis jirovecii.

Report any unusual symptoms to your healthcare provider immediately. Regular blood work (usually every 8-12 weeks once stable) is the best way to catch these side effects early.

Methotrexate is a high-alert medication. This means it carries a significant risk of causing serious harm if used incorrectly. The most critical safety rule for patients with RA or psoriasis is the WEEKLY dosing schedule. Errors where patients take the medication daily have resulted in numerous fatalities due to total bone marrow failure and gastrointestinal sloughing.

Methotrexate carries some of the most extensive Black Box Warnings in the FDA database. According to the official labeling:

• Pregnancy: Methotrexate is a potent teratogen. It must not be used by pregnant women or those planning to become pregnant. Both men and women should use effective contraception during and for at least 3 to 6 months after stopping the drug.
• Organ Toxicity: Serious and sometimes fatal toxicities involving the liver, lungs, kidneys, and bone marrow have been reported. These can occur without warning, though they are more common in patients with pre-existing conditions.
• NSAID Interaction: Concomitant use with nonsteroidal anti-inflammatory drugs (NSAIDs) can lead to unexpected, severe bone marrow suppression and GI toxicity because NSAIDs reduce the renal clearance of Methotrexate.
• Tumor Lysis Syndrome: In oncology patients with high tumor burdens, rapid cell kill can lead to metabolic imbalances.

• Allergic Reactions: Anaphylaxis and severe skin reactions (SJS/TEN) have been reported. If you develop a widespread rash or hives, stop the drug and seek emergency care.
• Infection Risk: Methotrexate is an immunosuppressant. You may be more susceptible to infections, and common infections may become more severe. Avoid contact with people who have contagious illnesses like the flu or chickenpox.
• Vaccinations: Live vaccines (such as the MMR or yellow fever vaccine) should generally be avoided while taking Methotrexate, as the suppressed immune system may allow the vaccine virus to replicate uncontrollably.
• Sun Exposure: Methotrexate can make your skin more sensitive to UV light. Use high-SPF sunscreen and wear protective clothing to avoid severe 'recall' sunburns.

To ensure safety, your healthcare provider will require regular laboratory monitoring. This typically includes:

• Complete Blood Count (CBC): To check for anemia (low red cells), leukopenia (low white cells), and thrombocytopenia (low platelets).
• Liver Function Tests (LFTs): To monitor for elevations in enzymes (ALT/AST) and bilirubin that indicate liver stress.
• Serum Creatinine: To assess kidney function and ensure the drug is being cleared from the body effectively.
• Chest X-ray: May be performed before starting therapy and if you develop respiratory symptoms to check for lung inflammation.

Methotrexate can cause dizziness, fatigue, and blurred vision, particularly in the 24 hours following your dose. Do not drive or operate heavy machinery until you know how the medication affects you.

Strict Avoidance Recommended: Alcohol significantly increases the risk of Methotrexate-induced hepatotoxicity (liver damage). Most clinical guidelines recommend that patients on Methotrexate abstain from alcohol entirely or limit intake to no more than one standard drink per week, and only if liver tests remain perfect.

Do not stop taking Methotrexate suddenly without consulting your doctor, as this can cause a 'flare' of your autoimmune symptoms. While there is no 'withdrawal syndrome' in the traditional sense, the underlying disease can worsen rapidly. If the drug must be stopped due to toxicity, your doctor will manage the transition to a different therapy.

> Important: Discuss all your medical conditions, especially lung, liver, or kidney disease, with your healthcare provider before starting Methotrexate.

• Live Vaccines: Vaccines such as the intranasal flu vaccine, MMR, and Varicella are contraindicated. The immune system may not be able to mount a proper response, leading to vaccine-induced illness.
• Nitrous Oxide: Use of nitrous oxide (laughing gas) during surgery or dental procedures in patients taking Methotrexate can result in severe, unpredictable bone marrow suppression and neurotoxicity due to its effect on folate metabolism.

• NSAIDs (e.g., Ibuprofen, Naproxen, Diclofenac): These are frequently used by RA patients but can be dangerous. NSAIDs compete with Methotrexate for excretion in the kidneys, leading to higher, toxic levels of Methotrexate in the blood. While often used together under strict supervision, the risk of toxicity is significantly increased.
• Proton Pump Inhibitors (PPIs) (e.g., Omeprazole, Pantoprazole): PPIs can interfere with the renal clearance of Methotrexate, potentially leading to toxic accumulation. Your doctor may suggest an H2 blocker (like Famotidine) as a safer alternative.
• Trimethoprim/Sulfamethoxazole (Bactrim): This antibiotic also acts as a folate antagonist. Combining it with Methotrexate can lead to 'double' folate inhibition, resulting in severe bone marrow failure.

• Penicillins: May reduce the renal clearance of Methotrexate.
• Theophylline: Methotrexate may decrease the clearance of theophylline, used for asthma, requiring dose adjustments of the latter.
• Retinoids (e.g., Acitretin): Increased risk of hepatotoxicity when used together for psoriasis.

• Caffeine: Some studies suggest that high caffeine intake may reduce the efficacy of Methotrexate in RA patients by interfering with the adenosine receptor pathway. If your symptoms are not well-controlled, your doctor may suggest limiting coffee intake.
• Dairy: High doses of dairy products at the time of oral administration might slightly decrease absorption, though this is rarely clinically relevant for weekly dosing.
• Folate-Rich Foods: While a healthy diet is encouraged, consuming massive amounts of folic acid-fortified foods simultaneously with your dose might theoretically reduce efficacy, though this is why daily supplementation is carefully timed.

• Echinacea: May interfere with the immunosuppressive effects of Methotrexate.
• St. John's Wort: Can affect liver enzymes and potentially alter the metabolism of various drugs, although its specific effect on Methotrexate is less clear than with other medications.
• Vitamin B9 (Folic Acid): While prescribed to reduce side effects, taking too much can potentially reduce the efficacy of the drug's anti-cancer properties. Always follow the specific dose prescribed by your doctor.

Methotrexate can interfere with certain laboratory tests:

• Skin Tests: It may suppress the response to tuberculin skin tests (PPD), leading to false-negative results.
• Blood Tests: It can cause elevations in uric acid levels, which may complicate the diagnosis of gout.

For each major interaction, the primary mechanism is usually renal competition (the drugs fight for the same exit door in the kidneys) or pharmacodynamic synergy (both drugs attack the same pathway, like folate metabolism). The consequence is almost always an increased risk of toxicity (low blood counts, mouth sores, liver damage). Management typically involves frequent blood monitoring or switching to a non-interacting alternative.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers.

In these scenarios, the risk of Methotrexate therapy almost always outweighs any potential benefit:

1. 1Pregnancy: Methotrexate is a known human teratogen (causes birth defects) and abortifacient (induces miscarriage). It is classified as Pregnancy Category X. It causes 'Methotrexate Embryopathy,' which includes skull defects, limb deformities, and developmental delays.
2. 2Breastfeeding: Methotrexate is excreted into breast milk and can cause serious harm to a nursing infant, including immune suppression and growth issues.
3. 3Alcoholism or Chronic Liver Disease: Patients with pre-existing cirrhosis, hepatitis, or a history of heavy alcohol use are at an extremely high risk for rapid liver failure when taking Methotrexate.
4. 4Immunodeficiency Syndromes: Patients with overt or laboratory evidence of immunodeficiency (e.g., advanced HIV/AIDS) should not take Methotrexate as it further cripples the immune response.
5. 5Pre-existing Blood Dyscrasias: Conditions like severe anemia, leukopenia, or thrombocytopenia are absolute contraindications because Methotrexate will worsen these life-threatening deficiencies.

These conditions require a careful risk-benefit analysis and intensive monitoring:

• Renal Impairment: Since the kidneys are the primary exit route, any decrease in function causes the drug to 'back up' in the system, leading to systemic toxicity.
• Active Infections: Treatment should usually be paused if a patient develops a significant infection (like pneumonia or a severe UTI) until the infection is cleared.
• Pulmonary Disease: Patients with pre-existing lung fibrosis or severe COPD may be at higher risk for Methotrexate-induced pneumonitis.
• Peptic Ulcer Disease: Methotrexate can cause GI irritation and may lead to perforation in patients with active ulcers.

While Methotrexate is a unique molecule, patients who have had severe hypersensitivity reactions to other folate antagonists (like Pemetrexed or Pralatrexate) should be approached with extreme caution, as cross-reactivity is possible. There is no known cross-sensitivity with common antibiotics like Penicillin or Sulfa drugs, though they may interact pharmacologically.

> Important: Your healthcare provider will evaluate your complete medical history, including a baseline chest X-ray and extensive blood work, before prescribing Methotrexate.

Methotrexate is one of the most dangerous medications to take during pregnancy. It is used clinically to terminate ectopic pregnancies because of its effectiveness at stopping fetal cell division.

• Risks: Exposure during the first trimester leads to a high rate of spontaneous abortion and 'Methotrexate-syndrome' in survivors (craniofacial, skeletal, and CNS malformations).
• Contraception: Female patients of childbearing age must have a negative pregnancy test before starting. Both men and women must use highly effective contraception. Women should wait at least one full ovulatory cycle (some guidelines say 6 months) after stopping Methotrexate before trying to conceive. Men should wait 3 to 6 months to ensure sperm quality is not affected.

Methotrexate passes into breast milk in low concentrations. However, because the drug can accumulate in neonatal tissues and has a high potential for toxicity (including suppression of the infant's developing immune system), breastfeeding is strictly contraindicated during therapy and for at least one week after the final dose.

Methotrexate is a standard treatment for polyarticular juvenile idiopathic arthritis (pJIA) in children aged 2 and older.

• Considerations: Children generally tolerate Methotrexate better than adults but require frequent monitoring of liver function and blood counts. There are concerns regarding the long-term impact on growth and fertility, though current data suggest that low-dose weekly therapy does not significantly impair normal development when monitored correctly.
• Oncology: It is a mainstay for pediatric ALL, where it is used in much higher doses under strict inpatient supervision.

Elderly patients (65+) are at a significantly higher risk for Methotrexate toxicity.

• Renal Function: Aging naturally reduces the glomerular filtration rate (GFR). Even if a 'normal' serum creatinine is seen, the actual clearance may be low.
• Polypharmacy: Seniors are more likely to be on interacting medications like PPIs or NSAIDs.
• Toxicity: Fatalities from bone marrow suppression are more common in the elderly. Doctors often start with very low doses (e.g., 5 mg to 7.5 mg weekly) for this population.

As Methotrexate is 80-90% renally excreted, kidney health is the most important factor in preventing toxicity.

• Dosing: For GFR < 60 mL/min, significant dose reductions are required. If GFR is < 30 mL/min, the drug is typically avoided entirely.
• Dialysis: Methotrexate is not effectively removed by standard hemodialysis. High-flux dialysis or glucarpidase may be needed in toxicity cases.

Patients with pre-existing hepatic impairment should not use Methotrexate. The drug can cause direct hepatotoxicity, leading to fibrosis and cirrhosis. In patients with obesity or diabetes (who may have non-alcoholic fatty liver disease), the risk of liver damage is increased, and more frequent LFT monitoring is required.

> Important: Special populations require individualized medical assessment and often more frequent laboratory monitoring than the general population.

Methotrexate is a competitive inhibitor of the enzyme dihydrofolate reductase (DHFR). Folates are essential for the synthesis of purines and pyrimidines, the building blocks of DNA and RNA. By binding to DHFR with an affinity 1,000 times greater than the natural substrate (dihydrofolate), Methotrexate prevents the formation of tetrahydrofolate (FH4).

In addition to DHFR, Methotrexate and its polyglutamated metabolites inhibit other folate-dependent enzymes, including thymidylate synthase and transformylases involved in purine synthesis. This results in a depletion of intracellular nucleotide pools, leading to the inhibition of DNA synthesis and repair. In autoimmune conditions, the inhibition of AICAR transformylase leads to the accumulation of intracellular AICAR, which subsequently increases extracellular adenosine levels. Adenosine then acts on A2A receptors to suppress inflammatory cell activity.

Methotrexate is cell-cycle S-phase specific. Its effects are most pronounced in tissues with high rates of cellular turnover, such as malignant cells, bone marrow, fetal cells, dermal epithelium, and the buccal/intestinal mucosa. The duration of effect is determined not just by the plasma concentration of the parent drug, but by the persistence of intracellular methotrexate polyglutamates, which can remain in tissues (like the liver and red blood cells) for weeks or even months.

| Parameter | Value |

|---|---|

| Bioavailability | 60% - 90% (Low dose); <60% (High dose) |

| Protein Binding | ~50% (Mainly Albumin) |

| Half-life | 3 - 10 hours (Low dose); 8 - 15 hours (High dose) |

| Tmax | 1 - 2 hours (Oral); 30 - 60 mins (IM) |

| Metabolism | Hepatic & Intracellular (Polyglutamation) |

| Excretion | Renal 80-90%, Fecal <10% |

• Molecular Formula: C20H22N8O5
• Molecular Weight: 454.44 g/mol
• Solubility: Practically insoluble in water, alcohol, and chloroform; soluble in dilute solutions of alkali hydroxides.
• Structure: It consists of a pteridine ring linked to p-aminobenzoic acid and L-glutamic acid. It is chemically very similar to folic acid, differing only by the substitution of an amino group for a hydroxyl group on the pteridine ring and a methyl group on the amino nitrogen.

Methotrexate is the prototypical folate analog metabolic inhibitor. Within rheumatology, it is the 'anchor' DMARD. Related medications in the antifolate class include Pemetrexed (Alimta) and Pralatrexate (Folotyn), though these are used exclusively in oncology and have different safety profiles.